1. Willingness of the patient by signing the informed consent.2. Subjects of any sex over 18 years of age.3. Subjects who in the run-in check have hematocrit = 40 and higher hemoglobin = 9 g / L and =14g / L.4. Subjects who maintain liver function tests in normal ranges or out of range in the pre-inclusion check-up without imminent compromise for life (clinical signs of hepatic encephalopathy and / or uremic coma).5. Patients with cardiovascular sequelae, classified as classes II-III according to the functional scale of the New York Health Association (NYHA).6. Patients with kidney sequelae with mild to moderate damage, according to the functional scale of the Kidney Disease Improving Global Outcome (KDIGO).7. Patients with respiratory clinical manifestations and deterioration of respiratory function due to spirometric or radiological functional pattern.8. Subjects of childbearing age who are using an adequate method of contraception prior to their inclusion in the study.

1. Willingness of the patient by signing the informed consent.2. Subjects of any sex over 18 years of age.3. Subjects who in the run-in check have hematocrit = 40 and higher hemoglobin = 9 g / L and =14g / L.4. Subjects who maintain liver function tests in normal ranges or out of range in the pre-inclusion check-up without imminent compromise for life (clinical signs of hepatic encephalopathy and / or uremic coma).5. Patients with cardiovascular sequelae, classified as classes II-III according to the functional scale of the New York Health Association (NYHA).6. Patients with kidney sequelae with mild to moderate damage, according to the functional scale of the Kidney Disease Improving Global Outcome (KDIGO).7. Patients with respiratory clinical manifestations and deterioration of respiratory function due to spirometric or radiological functional pattern.8. Subjects of childbearing age who are using an adequate method of contraception prior to their inclusion in the study.

1. Willingness of the patient by signing the informed consent.2. Subjects of any sex and age greater than or equal to 18 years.3. Functional status according to Karnofsky = 40%.4. Subjects who in the run-in check have hematocrit = 40 and higher hemoglobin = 9 g / L and =14g / L.5. Subjects who in the pre-inclusion check-up maintain liver function tests in normal ranges or out of range without imminent compromise for life (clinical signs of hepatic encephalopathy and / or uremic coma).6. Patients with cardiovascular sequelae classified in classes II-III according to the functional scale of the New York Health Association (NYHA).7. Patients with renal sequelae and mild to moderate damage, according to the classification of the state of renal function.8. Subjects of childbearing age who are using an adequate method of contraception prior to their inclusion in the study (intrauterine devices, hormonal contraceptives, barrier methods or tubal ligation). In the case of males (vasectomy, use of condoms).

1. Willingness of the patient by signing the informed consent.2. Subjects of any sex and age greater than or equal to 18 years.3. Functional status according to Karnofsky = 40%.4. Subjects who in the run-in check have hematocrit = 40 and higher hemoglobin = 9 g / L and =14g / L.5. Subjects who in the pre-inclusion check-up maintain liver function tests in normal ranges or out of range without imminent compromise for life (clinical signs of hepatic encephalopathy and / or uremic coma).6. Patients with cardiovascular sequelae classified in classes II-III according to the functional scale of the New York Health Association (NYHA).7. Patients with renal sequelae and mild to moderate damage, according to the classification of the state of renal function.8. Subjects of childbearing age who are using an adequate method of contraception prior to their inclusion in the study (intrauterine devices, hormonal contraceptives, barrier methods or tubal ligation). In the case of males (vasectomy, use of condoms).